In this study, we first confirmed that SGLT2 inhibitors indeed carry a risk of bladder cancer, and even bile duct cancer, with this risk being primarily concentrated in dapagliflozin and empagliflozin. This evidence concerns the gene SLC5A2 and bile duct cancer.